Research Topics
| V GuptaSummaryAffiliation: University of Toronto Country: Canada Publications
| Collaborators
|
Detail Information
Publications
Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or olderVikas Gupta
Blood and Marrow Transplant Program, Princess Margaret Hospital, Toronto, Ontario, Canada
Biol Blood Marrow Transplant 11:764-72. 2005..The reasonable disease control with nonmyeloablative transplantation in this high-risk group of patients merits further investigation...- Similar outcomes of cryopreserved allogeneic peripheral stem cell transplants (PBSCT) compared to fresh allograftsDong Hwan Kim
Department of Hematology Medical Oncology, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Canada
Biol Blood Marrow Transplant 13:1233-43. 2007..673), recurrence (P = .295), nonrelapse mortality (P = .340), and overall survival (P = .668) were not significantly different. It is therefore reasonable to consider the option of cryopreserved allografts... - Alternative donor transplants for high-risk acute myeloid leukemiaVikas Gupta
Blood and Marrow Transplant Program, Princess Margaret Hospital, University of Toronto, Toronto, Canada
Curr Opin Hematol 15:115-20. 2008..Although use of alternative donors in these patients is increasing, the role of alternative donors in these high-risk patients, especially in first remission, remains undefined... - Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemiaStephanie J Lee
Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Blood 112:3500-7. 2008..Acute graft-versus-host disease rates were similar between IM(+) and IM(-) groups regardless of leukemia phase. These results should be reassuring to patients receiving IM before HCT... - A prospective study comparing the outcomes and health-related quality of life in adult patients with myeloid malignancies undergoing allogeneic transplantation using myeloablative or reduced-intensity conditioningVikas Gupta
Blood and Marrow Transplant Program, Princess Margaret Hospital, University of Toronto, Ontario, Canada
Biol Blood Marrow Transplant 18:113-24. 2012..The trajectory of decline and recovery of HRQOL was similar between the 2 cohorts. We conclude that clinical outcomes and HRQOL in patients with myeloid malignancies undergoing RIC are not inferior to MAC at 1 year... - Clinico-biological features and prognostic significance of PML/RARalpha isoforms in adult patients with acute promyelocytic leukemia treated with all trans retinoic acid (ATRA) and chemotherapyVikas Gupta
Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Canada
Leuk Lymphoma 45:469-80. 2004..No difference in overall survival was seen between the two isoform groups (P 0.35). Our results suggest that based on molecular characterization, it may be possible to identify a subgroup of APL patients at higher-risk of relapse... - Favorable effect on acute and chronic graft-versus-host disease with cyclophosphamide and in vivo anti-CD52 monoclonal antibodies for marrow transplantation from HLA-identical sibling donors for acquired aplastic anemiaVikas Gupta
Department of Cellular and Molecular Sciences, Division of Haematology, St George s Hospital and Medical School, London, UK
Biol Blood Marrow Transplant 10:867-76. 2004..The favorable effect on the incidence and severity of GVHD is noteworthy in this study and warrants further investigation... - Allogeneic hematopoietic cell transplantation in human immunodeficiency virus-positive patients with hematologic disorders: a report from the center for international blood and marrow transplant researchVikas Gupta
Division of Haematology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
Biol Blood Marrow Transplant 15:864-71. 2009..Prospective studies are needed to evaluate the safety and efficacy of this modality in specific diseases in these patients... - Cavernous sinus thrombosis presenting with diplopia in an allogeneic bone marrow transplant recipientVikas Gupta
Department of Medical Oncology and Hematology, Princess Margaret Hospital University Health Network, Toronto, Ontario, Canada
Am J Hematol 77:77-81. 2004..Clinical course and serial radiological studies of this patient are described and correlated with autopsy findings... - Trisomy 4 as the sole cytogenetic abnormality in a patient with T-cell acute lymphoblastic leukemiaVikas Gupta
Department of Medical Oncology and Hematology, Princess Margaret Hospital University Health Network, University of Toronto, 610 University Avenue, Toronto, ON M5G 2M9, Canada
Cancer Genet Cytogenet 152:158-62. 2004..The present case is compared with the three previous reported cases of trisomy 4 in ALL. Due to the rarity of this cytogenetic abnormality, its prognostic significance in ALL remains unclear... - Myeloablative conditioning regimens for AML allografts: 30 years laterV Gupta
Department of Medical Oncology and Hematology, Princess Margaret Hospital Ontario Cancer Institute, Room 5 224, 610 University Avenue, Toronto, Ontario, Canada M5G 2M9
Bone Marrow Transplant 32:969-78. 2003..Further improvements may be possible from modifications of the standard regimens. Data from these latter studies seem to be encouraging, but are not based on comparative randomized trials... - Acute promyelocytic leukemia: a case-based reviewVikas Gupta
Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, Canada M5G 2M9
Hematology 8:105-13. 2003..The main aim of this review is to highlight recent progress made in the management of APL and address the role of maintenance therapy, prognostic factors for relapse and treatment of relapsed disease... - Prognostic significance of trisomy 4 as the sole cytogenetic abnormality in acute myeloid leukemiaVikas Gupta
Department of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, Room 5 224, 610 University Avenue, Toronto, Ont, Canada M5G 2M9
Leuk Res 27:983-91. 2003..Collaborations between major institutions and cooperative groups are needed to collect better quality data to understand the prognostic significance of such rare karyotypic abnormalities... - Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: myths, controversies, and unknownsVikas Gupta
Blood and Marrow Transplant Program, Princess Margaret Hospital, University of Toronto, 610 University Ave, Toronto, Ontario, Canada
Blood 117:2307-18. 2011..Continued study of HCT versus alternative therapies is required to optimize patients' outcomes in AML... - Imatinib Mesylate (Gleevec) is a useful agent in the salvage treatment of adults with relapsed/refractory Philadelphia positive acute leukemiasV Gupta
Department of Medical Oncology and Hematology, Princess Margeret Hospital, University of Toronto, Toronto, Canada
Hematology 8:139-43. 2003..Gleevec may prove to be a useful agent in the salvage therapy of such patients... - Graft-versus-host disease following marrow transplantation for aplastic anemia: different impact of two GVHD prevention strategiesD Siegal
Blood and Marrow Transplant Program, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
Bone Marrow Transplant 42:51-6. 2008..Our data suggest that 50-60 mg of alemtuzumab given according to the current schedule significantly reduces the risk of GVHD without increasing the risk of graft failure or serious infections... - A phase I/II study of imatinib plus reinduction therapy for c-kit-positive relapsed/refractory acute myeloid leukemia: inhibition of Akt activation correlates with complete responseJ M Brandwein
Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
Leukemia 25:945-52. 2011..These results indicate that lack of pAkt inhibition in vivo is associated with resistance to reinduction therapy using this regimen. Further studies using agents that are able to inhibit Akt more effectively are warranted... - Treatment of elderly patients with acute lymphoblastic leukemia--evidence for a benefit of imatinib in BCR-ABL positive patientsJ M Brandwein
Department of Medical Oncology, Princess Margaret Hospital, University Health Network, Toronto, Ont, Canada
Leuk Res 29:1381-6. 2005..Further regimens should explore the use of less aggressive regimens in elderly patients and should evaluate the optimal way of combining imatinib with conventional agents in BCR-ABL+ patients... - Long-term outcome after intensive therapy with etoposide, melphalan, total body irradiation and autotransplant for acute myeloid leukemiaP Mollee
Department of Hematology, University of Toronto Autologous Blood and Marrow Transplant Program, Princess Margaret Hospital Ontario Cancer Institute, Toronto, ON, Canada
Bone Marrow Transplant 33:1201-8. 2004..For patients in second remission approximately 30% can achieve cure with ABMT, and this option may be preferable to alternate donor allogeneic stem cell transplantation... - Marrow transplants from matched unrelated donors for aplastic anaemia using alemtuzumab, fludarabine and cyclophosphamide based conditioningV Gupta
Department of Cellular and Molecular Sciences, Division of Haematology, St George's Hospital and Medical School, London, UK
Bone Marrow Transplant 35:467-71. 2005.... - The role of allogeneic bone marrow transplantation in adult patients below the age of 55 years with acute lymphoblastic leukemia in first complete remission: a donor vs no donor comparisonV Gupta
Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, Canada
Bone Marrow Transplant 33:397-404. 2004..77). In conclusion, our data show that the policy of performing alloBMT if a sibling donor is available has not resulted in better outcome in Ph- patients... - Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapyVikas Gupta
Department of Medical Oncology and Hematology, Princess Margaret Hospital/University Health Network, Toronto, Ontario, Canada
Cancer 103:2082-90. 2005..CONCLUSIONS: The authors concluded that candidacy for intensive therapy in older patients should be based on biologic features of disease and fitness, rather than on age... - A phase I study of tipifarnib combined with conventional induction and consolidation therapy for previously untreated patients with acute myeloid leukemia aged 60 years and overJ M Brandwein
Department of Medical Oncology and Hematology, University of Toronto, Princess Margaret Hospital, Toronto, Canada
Leukemia 23:631-4. 2009..Tipifarnib 600 mg b.i.d. is considered the recommended dose for further study using this regimen... - Impact of intensity of conditioning therapy in patients aged 40-60 years with AML/myelodysplastic syndrome undergoing allogeneic transplantationM A Khabori
Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
Bone Marrow Transplant 46:516-22. 2011..45), EFS (HR: 1.73, 95% CI: 1.00-3.10) and cumulative relapse (HR: 3.24, 95% CI: 1.08-10.12). Disease biology rather than intensity of conditioning regimen seems to determine outcomes of alloHCT in patients aged 40-60 years with AML/MDS... - Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosisVikas Gupta
Princess Margaret Hospital, University of Toronto, Toronto, Ontario
Blood 116:1839-48. 2010..99, P = .05). Hematopoietic cell transplantation (HCT) using HLA-well-matched URD and MSD resulted in similar LFS and OS in AML patients in CR1 with unfavorable cytogenetics. Outcomes of HCT from HLA-partially- matched URD were inferior... - Clinical relevance of cytogenetic abnormalities at diagnosis of acquired aplastic anaemia in adultsVikas Gupta
Department of Haematology, St George's Hospital, London, UK
Br J Haematol 134:95-9. 2006..None of the patients with a non-numerical karyotypic abnormality responded. No significant differences in survival or later clonal disorders were observed between patients with a normal karyotype and those with an abnormal karyotype... - Evidence of graft-versus-Waldenstrom's macroglobulinaemia effect after allogeneic stem cell transplantation: a single centre experienceJ Stakiw
Allogeneic Blood and Marrow Transplantation Program, Princess Margaret Hospital, University of Toronto, 610 University Avenue, Toronto, Ontario, Canada
Bone Marrow Transplant 40:369-72. 2007..With the limited available data, it appears that allogeneic SCT is a useful treatment option for advanced WM... - Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimenJohn M Storring
Department of Medical Oncology and Haematology, Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada
Br J Haematol 146:76-85. 2009..Effective delivery of asparaginase dosing appears to be important in achieving an optimal antileukaemic effect... - Factors influencing varicella zoster virus infection after allogeneic peripheral blood stem cell transplantation: low-dose acyclovir prophylaxis and pre-transplant diagnosis of lymphoproliferative disordersD H Kim
Blood and Marrow Transplant Program, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
Transpl Infect Dis 10:90-8. 2008..However, no data have been reported on VZV infection after allogeneic peripheral blood stem cell transplantation (PBSCT)... - Quality of life beyond 6 months after diagnosis in older adults with acute myeloid leukemiaShabbir M H Alibhai
Division of General Internal Medicine and Clinical Epidemiology, University Health Network, Toronto, Canada
Crit Rev Oncol Hematol 69:168-74. 2009..This information may aid discussions with patients about treatment... - Central nervous system complications after allogeneic hematopoietic stem cell transplantation: incidence, manifestations, and clinical significanceDeborah Siegal
Blood and Marrow Transplant Program, University Health Network, Toronto, Canada
Biol Blood Marrow Transplant 13:1369-79. 2007..0001). Death from graft-versus-host disease (GVHD) was more common in patients with CNS complications in the first 100 days (P = .006) and PRES (P = .01) compared to patients without complications... - Predictors of response to reinduction chemotherapy for patients with acute myeloid leukemia who do not achieve complete remission with frontline induction chemotherapyJoseph M Brandwein
Department of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada
Am J Hematol 83:54-8. 2008..Patients achieving CR are at high risk of relapse and should be considered for allogeneic BMT or novel strategies to attempt to reduce relapse rates... - Favorable overall survival with fully myeloablative allogeneic stem cell transplantation for follicular lymphomaJohn Kuruvilla
Allogeneic Blood and Marrow Transplant Programme, Princess Margaret Hospital, Toronto, Canada
Biol Blood Marrow Transplant 14:775-82. 2008..4%, with an additional case of mortality from breast cancer. These results demonstrate that in selected younger patients, a fully myeloablative allo-SCT utilizing BuCy conditioning provides excellent OS and disease control with low TRM... - The impact of acute myeloid leukemia and its treatment on quality of life and functional status in older adultsShabbir M H Alibhai
Department of Medicine, University Health Network, Toronto, Canada
Crit Rev Oncol Hematol 64:19-30. 2007..Receiving IC does not appear to lead to worse QOL or functional status than more palliative approaches. This information may aid treatment discussions in older patients with AML... - Peripheral blood eosinophilia has a favorable prognostic impact on transplant outcomes after allogeneic peripheral blood stem cell transplantationDong Hwan Kim
Allogeneic Blood and Marrow Transplant Program, Department of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Canada
Biol Blood Marrow Transplant 15:471-82. 2009..In summary, the development of eosinophila after allogeneic PBSCT seemed to be a prognostic marker for improving transplant outcome... - Vascular events associated with alpha interferon therapyH Al-Zahrani
Department of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, 610 University Avenue, Toronto Ont, Canada, M5G 2M9
Leuk Lymphoma 44:471-5. 2003..Possible underlying mechanisms for these complications are discussed. The early diagnosis of these complications may be vital and IFN should be immediately discontinued when early signs of these complications become evident... - A third course of anti-thymocyte globulin in aplastic anaemia is only beneficial in previous respondersVikas Gupta
Division of Haematology, Department of Cellular and Molecular Sciences, St George's Hospital and Medical School, London, UK
Br J Haematol 129:110-7. 2005..Patients refractory to previous two courses of ATG have a much lower response rate and may be suitable candidates for novel therapeutic options... - Outcomes of older patients (> or = 60 years) with acquired aplastic anaemia treated with immunosuppressive therapySusan Y Kao
Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, ON, Canada
Br J Haematol 143:738-43. 2008..Nine out of 14 evaluable patients in the attenuated IST group had durable responses to treatment, suggesting that patients not suitable for standard IST can still benefit from attenuated IST... - Characteristics and outcomes of acute myelogenous leukemia patients with very late relapse (>5 years)Bruno C Medeiros
Department of Medical Oncology, Peincess Margaret Hospital, University Health Network, Univeristy of Toronto, Toronto, Ontario, Canada
Leuk Lymphoma 48:65-71. 2007..We conclude that very late-relapse AML is a rare event, and that reinduction in these patients is associated with very high CR rates and a potential cure fraction... - Anti-leukemia effect of ex vivo expanded DNT cells from AML patients: a potential novel autologous T-cell adoptive immunotherapyS Merims
Department of Laboratory Medicine and Pathobiology, Toronto General Research Institute, Toronto, Ontario, Canada
Leukemia 25:1415-22. 2011..These findings warrant studies further exploring the potential of DNT cells as a novel adjuvant immunotherapy to decrease the risk of relapse in patients with AML and, perhaps, other cancers... - Association of familial leukemia with HLA Cw3: is it real?J Kuruvilla
Department of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, Toronto, Canada M5G 2M9
Leuk Lymphoma 44:309-11. 2003..Phenomenon of anticipation is demonstrated in the affected family members. Possible causes of genetic susceptibility to leukemia especially the association of Cw3 with familial leukemia are discussed... - Outcome of patients who develop acute leukemia or myelodysplasia as a second malignancy after solid tumors treated surgically or with strategies that include chemotherapy and/or radiationArwa Abdelhameed
Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Canada
Cancer 112:1513-21. 2008..Evaluation of therapeutic outcomes and risk factors was undertaken for patients with primary solid tumors (PST) developing acute leukemia or myelodysplasia (MDS) as a second malignancy... - Clinical efficacy of prophylactic strategy of long-term low-dose acyclovir for Varicella-Zoster virus infection after allogeneic peripheral blood stem cell transplantationDong Hwan Kim
Allogeneic Blood and Marrow Transplant Program, Princess Margaret Hospital, University of Toronto, Toronto, Canada
Clin Transplant 22:770-9. 2008..04, hazard ratio = 0.296). Long-term use of acyclovir appears to be protective for VZV infection after allogeneic PBSCT, especially during the period of immunosuppressive therapy... - Acute lung injury during antithymocyte globulin therapy for aplastic anemiaEwan Christopher Goligher
Department of Medicine, University of Toronto, Toronto, Ontario, Canada
Can Respir J 16:e3-5. 2009..ATG-related toxicity should be included in the differential diagnosis of new, infusion-associated pulmonary infiltrates, and corticosteroids may be a useful therapeutic consideration in the management... - Improved survival using an intensive, pediatric-based chemotherapy regimen in adults with T-cell acute lymphoblastic leukemiaMurtadha Al-Khabori
Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada
Leuk Lymphoma 51:61-5. 2010..non-DFCI) was the major prognostic factor influencing both RFS and OS. The results provide evidence supporting the superior efficacy of asparaginase-intensive pediatric-based regimens for adults with T-ALL... - Predictive value of karyotype on outcome of autotransplants for acute myeloid leukemia in second remissionKevin W Song
The Leukemia Bone Marrow Transplantation Program of British Columbia, Vancouver Hospital and Health Sciences Center, British Columbia Cancer Agency, University of British Columbia, Vancouver, British Columbia, Canada
Leuk Lymphoma 46:525-31. 2005..5-63.9); unknown 2.3 (0.6-8.8) (P=0.028). We conclude that patients with AML in CR2 who undergo autotransplant can have durable remissions and those with a good risk karyotype are the most likely to obtain long-term disease-free survival... - Role of all-trans-retinoic acid (ATRA) in the consolidation therapy of acute promyelocytic leukaemia (APL)Vikas Gupta
Leuk Res 29:113-4. 2005..The role of ATRA during consolidation therapy of APL merits further investigation as this may allow shortening the overall duration of APL treatment... - Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remissionDavid I Marks
Adult Blood and Marrow Transplantation BMT Unit, United Bristol Healthcare Trust, Bristol, United Kingdom
Blood 112:426-34. 2008..Nearly 40% of adults with ALL in CR1 survive 5 years after URD transplantation. Relapse risks were modest; TRM is the major cause of treatment failure. Selecting closely HLA-matched URD and reducing TRM should improve results... - Surgical management and outcome of tuberculous atlantoaxial dislocation: a 15-year experienceSanjiv Sinha
Department of Neurosurgery, G B Pant Hospital, Maulana Azad Medical College, University of Delhi, New Delhi, India
Neurosurgery 52:331-8; discussion 338-9. 2003..The management of tuberculous atlantoaxial dislocation includes ventral cervicomedullary decompression, occipitocervical arthrodesis, and administration of antituberculous medications... - Megaesophagus after fundoplicationNarendar Mohan Gupta
Am J Gastroenterol 98:2581-3. 2003 - Esophageal perforation caused by a blister-wrapped tabletNarendar Mohan Gupta
Department of Surgery, Postgraduate Institute of Medical Education and Research Chandigarh, Punjab, India
Asian Cardiovasc Thorac Ann 10:87-8. 2002..An 84-year-old man was diagnosed with esophageal perforation following ingestion of a blister-wrapped tablet. His condition improved after 2 weeks of conservative treatment using antibiotics and high-protein enteral nutrition... - Recurrent osteoid osteoma: a case report with imaging featuresRakesh Kumar
Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India
Clin Imaging 27:269-72. 2003..Computerized tomography confirmed the findings of skeletal scintigraphy... - Acute promyelocytic leukemia in patients aged 70 years and over -- a single center experience of unselected patientsPatricia Disperati
Leuk Lymphoma 48:1654-8. 2007 - Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumoniaMarin H Kollef
Washington University School of Medicine, 660 South Euclid Ave, St Louis, MO 63110, USA
Chest 128:3854-62. 2005..Accumulating evidence suggests that health-care-associated infections are distinct from those that are truly community acquired... - Acute nephritis induced by human parvovirus B 19 infectionVikas Gupta
Nephrol Dial Transplant 22:2102. 2007